DBV Technologies Stock Bounces Back 4%, Recording One of the Top Gains in the SBF 120
The French biotech significantly recovers mid-day, going against the grain of a heavily penalized Paris market due to geopolitical tensions. The stock joins the leaders of the broad index, erasing some of the decline accumulated over three months. However, the declared short positions remain at a high level.
A Significant Rebound Bringing the Stock Above its 20-Day Moving Average
DBV Technologies stock gains 4.04% to €2.99 during the session, while the SBF 120 drops by 2.23% and the CAC 40 decreases by 2.26% in an atmosphere weighed down by the escalation between Washington and Tehran. The stock is among the highest risers in the SBF 120, led by oil and oil-related values. The rebound brings the weekly performance to +6%, allowing the price to move back above the 20-day moving average (MM20) at €2.87, with a gap of +4.18%. However, longer moving averages remain above the current price: the 50-day moving average at €3.11 and the 200-day moving average at €3.12 represent a dynamic resistance close to 3.86% above the current level. The RSI at 46 indicates a neutral configuration, consistent with the oscillating movement observed since mid-June around the €2.75 support level, which was broken and regained multiple times. This €2.75 support remains a key technical benchmark for the stock, as reminded by the session on July 2 when it was breached. The next resistance is at €3.36, which is just over 12% above current levels.
A U.S. Regulatory Filing that Structures the Horizon, Amidst Sustained Shorts
Today's rebound occurs as the biotech prepares to file its BLA with the FDA for Viaskin Peanut, scheduled for the third quarter of 2026 for children aged 4 to 7 years allergic to peanuts. This regulatory milestone is added to the positive data from the phase 3 VITESSE study presented in early June at the EAACI congress. Concurrently, the company joined the Euronext Tech Leaders index on June 22, a sector recognition that is part of an annual performance still largely positive, at +62% over twelve months. According to reviewed declarations, the cumulative net short position reaches 3.36% of the capital, carried by three funds, up by 0.55 points over thirty days. This level, higher than the often-used 3% threshold, signals the persistence of a structured bearish bet approaching the FDA filing. The selling pressure has not eased over the past month, which mechanically limits the amplitude of technical rebounds like the one observed today. The next operational milestone remains the submission of the BLA dossier in Q3 2026.
